Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study J Am Coll Cardiol Intv. 2016;9(11): doi: /j.jcin Study Design Platelet function tests included VerifyNow P2Y12 point-of-care testing, whole blood vasodilator-stimulated phosphoprotein, and light transmittance aggregometry. LD = loading dose; MD = maintenance dose. Figure Legend:

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study J Am Coll Cardiol Intv. 2016;9(11): doi: /j.jcin Subject Disposition The treated population (n = 82) comprised all randomized patients who received any dose of study medication and was considered for safety analysis. The primary population (n = 79) was defined as patients who received the randomized treatment and had valid primary endpoint data (P2Y12 reaction units at 1 week), and was used for analysis of all pharmacodynamic endpoints. Figure Legend:

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study J Am Coll Cardiol Intv. 2016;9(11): doi: /j.jcin Pharmacodynamic Comparisons Among Groups Comparison in platelet reactivity across time points among ticagrelor 180 mg loading dose (LD) group (Tic 180 mg), ticagrelor 90 mg bid maintenance dose (MD) without LD group (Tic 90 mg), and prasugrel 10 mg QD MD group (Pras 10 mg). Platelet reactivity was measured by (A) VerifyNow P2Y12; (B) whole blood vasodilator-stimulated phosphoprotein; and (C) light transmittance aggregometry with 20 μM adenosine diphosphate (ADP). The p values represent the comparisons among the 3 groups at each time point. Histograms represent least squares means. Error bars represent 95% confidence interval. MPA = maximal platelet aggregation; Pras = prasugrel; Tic = ticagrelor. Figure Legend:

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study J Am Coll Cardiol Intv. 2016;9(11): doi: /j.jcin Platelet Reactivity Over Time Measured by VerifyNow P2Y12 The main figure represents P2Y12 reaction units (PRU) over time in ticagrelor 180 mg loading dose (LD) group (Tic 180 mg), ticagrelor 90 mg bid maintenance dose (MD) without LD group (Tic 90 mg), ticagrelor combined group (Tic combined), and prasugrel 10 mg QD MD group (Pras 10 mg). Results are reported as least squares means. *p < for the comparison of Tic combined versus Pras 10 mg. The box in the right upper corner represents the primary endpoint: 1-week PRU absolute difference and 2-sided 95% confidence interval between Tic combined and Pras 10 mg. Tinted area indicated zone of noninferiority. The dotted line represents the pre-specified limit of noninferiority of +45. Figure Legend:

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study J Am Coll Cardiol Intv. 2016;9(11): doi: /j.jcin Platelet Reactivity Over Time Measured by VASP and Light Transmittance Aggregometry (A) Platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) and (B) maximal platelet aggregation (MPA) measured by light transmittance aggregometry over time in ticagrelor 180 mg loading dose (LD) group (Tic 180 mg), ticagrelor 90 mg bid maintenance dose (MD) without LD group (Tic 90 mg), ticagrelor combined group (Tic combined), and prasugrel 10 mg QD MD group (Pras 10 mg). Results are reported as least square means. *p < for the comparison of Tic combined versus Pras 10 mg. Abbreviations as in Figure 3. Figure Legend: